Testimony Before the FDA’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee Regarding the Opioid Oxycodegol

View as PDF

View press release

In testimony before a joint meeting of the Food and Drug Administration’s Anesthetic and Analgesic Drug Products Advisory Committee and Drug Safety and Risk Management Advisory Committee, Public Citizen urged the committees to recommend that the FDA not approve the new opioid oxycodegol, which is closely related to oxycodone, for treatment of chronic low back pain because the medication is not effective for treating this condition but has oral abuse potential comparable to currently approved oxycodone products.

See Public Citizen’s other work on opioid drug issues.